Health Canada Drugs & Medical Devices Brief

Headline

Health Canada updates TZIELD product monograph to add contraindications and viral reactivation screening requirements

Executive Summary

Health Canada, in collaboration with sanofi-aventis Canada Inc., issued a safety communication on September 14, 2026 updating the Canadian Product Monograph for TZIELD (teplizumab). The update adds a contraindication for immunocompromised patients and those with active viral infections. It also mandates pre-treatment EBV and CMV screening, with confirmed undetectable viral load required before initiation.

Bottom Line

The updated Canadian Product Monograph closes access to TZIELD for immunocompromised patients and those with active viral or serious infections, effective as of the communication date. Every TZIELD initiation in Canada now requires confirmed undetectable EBV and CMV viral load before the first dose, adding a mandatory laboratory step to the pre-treatment workflow. Prescribers who continue TZIELD in patients who develop confirmed EBV or CMV infection, or who develop prolonged severe lymphopenia below 0.5 x 10⁹ lymphocytes per litre for one week or longer, are operating outside the updated label. The post-market basis for the update, cases of life-threatening reactivation including EBV-associated lymphoproliferative disorder, places the monitoring obligation on all treating clinicians for at least two months after the final infusion.

Key Regulatory Signals

• New Contraindication Across Three Patient Categories: TZIELD is now contraindicated in patients with an active viral infection (including EBV or CMV), any active serious infection, or who are immunocompromised. Prescribers must screen and exclude patients in any of these three categories before initiating treatment.
• Mandatory Pre-Treatment Viral Load Testing: Before initiating TZIELD, healthcare professionals must evaluate patients for active EBV and CMV infection and confirm an undetectable viral load, such as by polymerase chain reaction testing. This requirement is additive to existing pre-treatment laboratory evaluations already in place.
• Post-Treatment Monitoring Window Extended to Two Months: Patients must be monitored for signs and symptoms of infection, including viral reactivation, during treatment and for at least two months following the last infusion. Lymphocyte counts must be monitored throughout the treatment period.
• Permanent Discontinuation Triggers Now Codified: Confirmed EBV or CMV infection requires permanent discontinuation of TZIELD and initiation of appropriate treatment. Prolonged severe lymphopenia, defined as fewer than 0.5 x 10⁹ lymphocytes per litre lasting one week or longer, also requires permanent discontinuation.
• Post-Market Signal Drove the Update: The safety communication is based on serious and life-threatening viral reactivation cases reported in the post-market setting. Most cases occurred within two months of the last infusion; some occurred in patients who continued treatment despite persistent severe lymphopenia.

Regulatory Delta

- No prior Health Canada safety communication specific to TZIELD viral reactivation has been identified. This product monograph update represents the first formal contraindication and screening mandate for this agent in Canada.

- The update converts what were previously monitoring recommendations into binding contraindications and mandatory pre-treatment testing steps, materially raising the pre-prescribing burden for all TZIELD initiations.

- The U.S. FDA-approved prescribing information for TZIELD already carries warnings about serious infections and lymphopenia. The Canadian action goes further, adding a formal contraindication and explicit EBV and CMV pre-treatment screening requirements not previously codified in the Canadian label.

Materiality Classification

MEDIUM — Health Canada product monograph update imposes new contraindications and mandatory pre-treatment viral load screening on all Canadian prescribers initiating TZIELD, requiring immediate workflow and patient-assessment changes across the relevant clinical population.

Intelligence Outlook

Monitor Health Canada's Recalls and Safety Alerts Database and the MedEffect e-Notice system for any further updates to the TZIELD product monograph or additional safety communications regarding viral reactivation in immunomodulatory agents.